This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Pinewood Healthcare

Ballymacarby, Clonmel, Co. Tipperary, Co. Tipperary, Ireland
Telephone: +353 52 6186000
Fax: + 353 52 6136311
WWW: http://www.pinewood.ie
Medical Information Direct Line: +44 1978 661 261
Medical Information e-mail: drug.safety@wockhardt.co.uk
Medical Information Fax: +44 1978 661 702

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 16/08/2013
SPC Codeine Linctus BP


Go to top of the page
1. Name of the medicinal product

Codeine Linctus BP


Go to top of the page
2. Qualitative and quantitative composition

Each 5 ml of Codeine Linctus BP contains 15 mg of Codeine Phosphate BP.


Go to top of the page
3. Pharmaceutical form

Clear yellow, lemon flavoured syrup.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Recommended as an anti-tussive for a non productive cough by oral administration.


Go to top of the page
4.2 Posology and method of administration

The usual dosage for adults is 5 to 10 ml, 3 to 4 times daily. Dosage should be reduced in elderly or debilitated patients.


Go to top of the page
4.3 Contraindications

Hypersensitivity to Codeine.

Liver disease: drug may accumulate.

Ventilatory failure condition may be exacerbated.


Go to top of the page
4.4 Special warnings and precautions for use

Geriatric patients should be supervised while on this medication, and consideration of reduced dosage should be based on response. Codeine should only be used with caution in patients with kidney or liver impairment. Care should be taken in patients with asthma, hypothyroidism, and in patients with a history of drug abuse. Tolerance and dependency may occur with prolonged use.

Codeine is partially metabolised by CYP2D6. If a patient has a deficiency or is completely lacking this enzyme they will not obtain adequate analgesic effects. Estimates indicate that up to 7% of the caucasian population may have this deficiency. However, if the patient is an ultra-rapid metaboliser there is an increased risk of developing side effects of opioid toxicity even at low doses. General symptoms of opioid toxicity include nausea, vomiting, constipation, lack of appetite and somnolence. In severe cases this may include symptoms of circulatory and respiratory depression. Estimates indicate that up to 1 to 2% of the caucasian population may be ultra-rapid metabolisers.

Sunset Yellow may cause allergic reactions.

This product contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

CNS depressants, anticholinergics, hydroxyzine and methadone – concurrent use of these medicines may result in potentiation of effects and hypotensive effects and CNS depressant effects may be increased; levallorphan is a morphine antagonist; the respiratory effects of neuromuscular blocking agents may be addictive to the central respiratory effects of the opioid analgesics; metoclopramide and codeine have opposing effects on gastro – intestinal activity; codeine causes delayed absorption of mexiletine; the effects of hypnotics and sedatives may be potentiated by codeine; hypertensive crisis may be caused by concurrent use of codeine and monoamine – oxidase inhibitors.


Go to top of the page
4.6 Fertility, pregnancy and lactation

Risk – benefit must be considered before using codeine during pregnancy or lactation. Codeine crosses the placenta and is excreted in small amounts in breast milk. Regular use during pregnancy may cause physical dependency in the foetus, depression of neonatal respiration, withdrawal effects in the neonate. Teratogenic effects in humans have not been documented but controlled studies have not been done. There is a risk of gastric stasis in the mother during labour which may lead to inhalation pneumonia.

At normal therapeutic doses codeine may be present in breast milk at very low doses and is unlikely to adversely affect the breast fed infant. However, if the patient is an ultra-rapid metaboliser of CYP2D6, higher levels of codeine may be present in breast milk and on very rare occasions may result in symptoms of opioid toxicity in the infant.

If symptoms of opioid toxicity develop in either the mother or the infant, then all codeine containing medicines should be stopped and alternative non-opioid analgesics prescribed. In severe cases consideration should be given to prescribing naloxone to reverse these effects.


Go to top of the page
4.7 Effects on ability to drive and use machines

Codeine may cause drowsiness. Patients receiving this medication should not drive or operate machinery unless it has been shown not to affect mental or physical ability.


Go to top of the page
4.8 Undesirable effects

Gastrointestinal side effects, constipation is not uncommon; loss of appetite; flushing of face might occasionally occur; respiratory depression may be experienced; sputum retention may occur particularly in patients with chronic bronchitis and bronchiectasis.


Go to top of the page
4.9 Overdose

In cases of overdosage supportive therapy is recommended. Gastric lavage should be carried out and a saline purgative may then be given to reduce absorption from gastro – intestinal tract. Symptomatic treatment of respiratory embarrassment should be given. If respiration is seriously depressed intravenous naloxone HCl may be required.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Morphine derivative. Antitussive – suppresses the cough reflex by a direct central action, probably in the medulla or pons.


Go to top of the page
5.2 Pharmacokinetic properties

Protein binding is very low.

Half life from 2.5 to 4 hours.

Duration of action approximately 4 hours.

Onset of action after oral administration is 30 to 45 minutes.

Excretion is primarily renal with 5 to 15% of the drug excreted unchanged.


Go to top of the page
5.3 Preclinical safety data

Not applicable


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Sodium Benzoate (E211)

Citric Acid Monohydrate

Saccharin Sodium (E954)

Sunset Yellow (E110)

Sorbitol Solution 70% (E420)

Purified Water (to volume)

Orange Flavour

Carboxymethylcellulose 7H3SFX

Propylene Glycol


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

High density polyethylene Bottles:

36 months

Amber glass Bottles:

36 months


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C. Protect from light.


Go to top of the page
6.5 Nature and contents of container

Pharmaceutical Grade III Amber Glass Bottles with CRC caps:

100 ml, 125 ml and 200 ml

High Density Polyethylene Bottles:

2000 ml and 1000 ml


Go to top of the page
6.6 Special precautions for disposal and other handling

As for all medicines – no special warnings.


Go to top of the page
7. Marketing authorisation holder

Pinewood Laboratories Ltd.,

Ballymacarbry,

Clonmel,

Co. Tipperary,

Ireland.


Go to top of the page
8. Marketing authorisation number(s)

PL 04917/0001


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

30/08/1998 / 20/11/2003


Go to top of the page
10. Date of revision of the text

May 2013



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/24373/SPC/


Active Ingredients/Generics